219 related articles for article (PubMed ID: 32564774)
1. Bevacizumab dose adjustment to improve clinical outcomes of glioblastoma.
García-Romero N; Palacín-Aliana I; Madurga R; Carrión-Navarro J; Esteban-Rubio S; Jiménez B; Collazo A; Pérez-Rodríguez F; Ortiz de Mendivil A; Fernández-Carballal C; García-Duque S; Diamantopoulos-Fernández J; Belda-Iniesta C; Prat-Acín R; Sánchez-Gómez P; Calvo E; Ayuso-Sacido A
BMC Med; 2020 Jun; 18(1):142. PubMed ID: 32564774
[TBL] [Abstract][Full Text] [Related]
2. Use of bevacizumab in recurrent glioblastoma.
Ghiaseddin A; Peters KB
CNS Oncol; 2015; 4(3):157-69. PubMed ID: 25906439
[TBL] [Abstract][Full Text] [Related]
3. Hypoxia upregulates HIG2 expression and contributes to bevacizumab resistance in glioblastoma.
Mao XG; Wang C; Liu DY; Zhang X; Wang L; Yan M; Zhang W; Zhu J; Li ZC; Mi C; Tian JY; Hou GD; Miao SY; Song ZX; Li JC; Xue XY
Oncotarget; 2016 Jul; 7(30):47808-47820. PubMed ID: 27329597
[TBL] [Abstract][Full Text] [Related]
4. Increased Antiangiogenic Effect by Blocking CCL2-dependent Macrophages in a Rodent Glioblastoma Model: Correlation Study with Dynamic Susceptibility Contrast Perfusion MRI.
Cho HR; Kumari N; Thi Vu H; Kim H; Park CK; Choi SH
Sci Rep; 2019 Jul; 9(1):11085. PubMed ID: 31366997
[TBL] [Abstract][Full Text] [Related]
5. Phase II study of panobinostat in combination with bevacizumab for recurrent glioblastoma and anaplastic glioma.
Lee EQ; Reardon DA; Schiff D; Drappatz J; Muzikansky A; Grimm SA; Norden AD; Nayak L; Beroukhim R; Rinne ML; Chi AS; Batchelor TT; Hempfling K; McCluskey C; Smith KH; Gaffey SC; Wrigley B; Ligon KL; Raizer JJ; Wen PY
Neuro Oncol; 2015 Jun; 17(6):862-7. PubMed ID: 25572329
[TBL] [Abstract][Full Text] [Related]
6. Antiangiogenic therapy for high-grade glioma.
Khasraw M; Ameratunga MS; Grant R; Wheeler H; Pavlakis N
Cochrane Database Syst Rev; 2014 Sep; (9):CD008218. PubMed ID: 25242542
[TBL] [Abstract][Full Text] [Related]
7. Preclinical impact of bevacizumab on brain and tumor distribution of irinotecan and temozolomide.
Goldwirt L; Beccaria K; Carpentier A; Idbaih A; Schmitt C; Levasseur C; Labussiere M; Milane A; Farinotti R; Fernandez C
J Neurooncol; 2015 Apr; 122(2):273-81. PubMed ID: 25794638
[TBL] [Abstract][Full Text] [Related]
8. Bevacizumab-induced hypertension is a predictive marker for improved outcomes in patients with recurrent glioblastoma treated with bevacizumab.
Zhong J; Ali AN; Voloschin AD; Liu Y; Curran WJ; Crocker IR; Shu HK
Cancer; 2015 May; 121(9):1456-62. PubMed ID: 25557543
[TBL] [Abstract][Full Text] [Related]
9. Enhanced anti-angiogenic effects of bevacizumab in glioblastoma treatment upon intranasal administration in polymeric nanoparticles.
Sousa F; Dhaliwal HK; Gattacceca F; Sarmento B; Amiji MM
J Control Release; 2019 Sep; 309():37-47. PubMed ID: 31344424
[TBL] [Abstract][Full Text] [Related]
10. Bevacizumab in high-grade gliomas: past, present, and future.
Curry RC; Dahiya S; Alva Venur V; Raizer JJ; Ahluwalia MS
Expert Rev Anticancer Ther; 2015 Apr; 15(4):387-97. PubMed ID: 25797685
[TBL] [Abstract][Full Text] [Related]
11. Phase II trial of ponatinib in patients with bevacizumab-refractory glioblastoma.
Lee EQ; Muzikansky A; Duda DG; Gaffey S; Dietrich J; Nayak L; Chukwueke UN; Beroukhim R; Doherty L; Laub CK; LaFrankie D; Fontana B; Stefanik J; Ruland S; Caruso V; Bruno J; Ligon K; Reardon DA; Wen PY
Cancer Med; 2019 Oct; 8(13):5988-5994. PubMed ID: 31444999
[TBL] [Abstract][Full Text] [Related]
12. Effects of anti-angiogenesis on glioblastoma growth and migration: model to clinical predictions.
Scribner E; Saut O; Province P; Bag A; Colin T; Fathallah-Shaykh HM
PLoS One; 2014; 9(12):e115018. PubMed ID: 25506702
[TBL] [Abstract][Full Text] [Related]
13. Plasmatic MMP9 released from tumor-infiltrating neutrophils is predictive for bevacizumab efficacy in glioblastoma patients: an AVAglio ancillary study.
Jiguet-Jiglaire C; Boissonneau S; Denicolai E; Hein V; Lasseur R; Garcia J; Romain S; Appay R; Graillon T; Mason W; Carpentier AF; Brandes AA; Ouafik L'; Wick W; Baaziz A; Gigan JP; Argüello RJ; Figarella-Branger D; Chinot O; Tabouret E
Acta Neuropathol Commun; 2022 Jan; 10(1):1. PubMed ID: 34980260
[TBL] [Abstract][Full Text] [Related]
14. Different Timing to Use Bevacizumab in Patients with Recurrent Glioblastoma: Early
Pasqualetti F; Gonnelli A; Molinari A; Cantarella M; Montrone S; Cristaudo A; Baldaccini D; Mattioni R; Delishaj D; Mazzotti V; Morganti R; Cocuzza P; Fabrini MG; Lombardi G; Rudà R; Soffietti R; Paiar F
Anticancer Res; 2018 Oct; 38(10):5877-5881. PubMed ID: 30275213
[TBL] [Abstract][Full Text] [Related]
15. Regulation of hypoxia-induced autophagy in glioblastoma involves ATG9A.
Abdul Rahim SA; Dirkse A; Oudin A; Schuster A; Bohler J; Barthelemy V; Muller A; Vallar L; Janji B; Golebiewska A; Niclou SP
Br J Cancer; 2017 Sep; 117(6):813-825. PubMed ID: 28797031
[TBL] [Abstract][Full Text] [Related]
16. Neuropilin-1 modulates TGFβ signaling to drive glioblastoma growth and recurrence after anti-angiogenic therapy.
Kwiatkowski SC; Guerrero PA; Hirota S; Chen Z; Morales JE; Aghi M; McCarty JH
PLoS One; 2017; 12(9):e0185065. PubMed ID: 28938007
[TBL] [Abstract][Full Text] [Related]
17. Phase 1 dose-escalation study of the antiplacental growth factor monoclonal antibody RO5323441 combined with bevacizumab in patients with recurrent glioblastoma.
Lassen U; Chinot OL; McBain C; Mau-Sørensen M; Larsen VA; Barrie M; Roth P; Krieter O; Wang K; Habben K; Tessier J; Lahr A; Weller M
Neuro Oncol; 2015 Jul; 17(7):1007-15. PubMed ID: 25665807
[TBL] [Abstract][Full Text] [Related]
18. Efficacy of Combination Therapy with MET and VEGF Inhibitors for MET-overexpressing Glioblastoma.
Okuda T; Tasaki T; Nakata S; Yamashita K; Yoshioka H; Izumoto S; Kato A; Fujita M
Anticancer Res; 2017 Jul; 37(7):3871-3876. PubMed ID: 28668888
[TBL] [Abstract][Full Text] [Related]
19. The Role of a Single Angiogenesis Inhibitor in the Treatment of Recurrent Glioblastoma Multiforme: A Meta-Analysis and Systematic Review.
Wang Y; Xing D; Zhao M; Wang J; Yang Y
PLoS One; 2016; 11(3):e0152170. PubMed ID: 27007828
[TBL] [Abstract][Full Text] [Related]
20. Hypoxia suppresses cylindromatosis (CYLD) expression to promote inflammation in glioblastoma: possible link to acquired resistance to anti-VEGF therapy.
Guo J; Shinriki S; Su Y; Nakamura T; Hayashi M; Tsuda Y; Murakami Y; Tasaki M; Hide T; Takezaki T; Kuratsu J; Yamashita S; Ueda M; Li JD; Ando Y; Jono H
Oncotarget; 2014 Aug; 5(15):6353-64. PubMed ID: 25071012
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
